Compare CCHH & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCHH | COCP |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 21.6M |
| IPO Year | 2025 | 2011 |
| Metric | CCHH | COCP |
|---|---|---|
| Price | $0.87 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 27.9K | ★ 41.6K |
| Earning Date | 11-29-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.76 |
| 52 Week High | $15.39 | $2.03 |
| Indicator | CCHH | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 31.39 |
| Support Level | $0.86 | $0.86 |
| Resistance Level | $1.08 | $1.11 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 11.22 | 18.42 |
CCH Holdings Ltd, through its subsidiaries, operates a specialty hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot. The Group offers catering services in Malaysia and outside Malaysia, mainly under two brands, namely Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants. It operates or licenses several restaurant outlets, among which include Chicken Claypot House, Zi Wei Yuan, 888 Family Food Courts, and other outlets under the Bibixian, Banbudian Bistro, and Chao Liu Xian Hotpot brands. A large share of its restaurants are located in Malaysia, with additional franchised outlets in Thailand, Indonesia, and China. Geographically, the Group's revenues are all derived from Malaysia.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.